A5024873802- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Cancer therapeutics and mechanisms
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Bone health and treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Drug Transport and Resistance Mechanisms
- Chemokine receptors and signaling
- Cholinesterase and Neurodegenerative Diseases
- Cancer Mechanisms and Therapy
- Bone and Joint Diseases
- Complement system in diseases
- Biosimilars and Bioanalytical Methods
- Cell Adhesion Molecules Research
- PI3K/AKT/mTOR signaling in cancer
- Research on Leishmaniasis Studies
- Hematological disorders and diagnostics
- Science, Research, and Medicine
Université de Lille
2021-2025
Centre Hospitalier Universitaire de Lille
2018-2025
Rigshospitalet
2001-2021
Copenhagen University Hospital
2014-2021
University of Copenhagen
2003-2019
Kiel University
1995
Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils light chains produced clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease. We randomly assigned patients with newly diagnosed AL to receive six cycles bortezomib, cyclophosphamide, and dexamethasone either alone (control group) or subcutaneous daratumumab followed single-agent every 4 weeks up 24 (daratumumab group). The primary end...
Abstract In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib (Vd) in patients with relapsed or refractory multiple myeloma previously treated lenalidomide, including those to lenalidomide. This analysis evaluated outcomes at first relapse ( N = 226) by lenalidomide-refractory status, prior exposure, stem cell transplant (SCT). Second-line PVd significantly improved PFS Vd (17.8 9.5 months; P 0.0276)...
Several risk scores for disease progression in patients with smoldering multiple myeloma (SMM) have been proposed; however, all developed using single-center registries. To examine factors time to (TTP) (MM) SMM, we analyzed a nationwide population-based cohort of 321 newly diagnosed SMM registered within the Danish Multiple Myeloma Registry between 2005 and 2014. Significant univariable TTP were selected multivariable Cox regression analyses. We found that both an M-protein ≥30 g/L...
Cardiac amyloidosis (CA) has been associated with poor outcomes. Screening studies suggest that CA is overlooked-especially in the elderly. Recent advances treatment have brought attention to disease, but data on temporal changes epidemiology are sparse.The aim of this work was describe all patients Denmark, examining patient characteristics from 1998 2017.All any form diagnosed 2017, as well their comorbidities and pharmacotherapy, were identified Danish nationwide registries. defined...
Immunoparesis (hypogammaglobulinemia) is associated to an unfavorable prognosis in newly diagnosed Multiple myeloma (MM) patients. However, this finding has not been validated unselected population-based cohort. We analyzed 2558 MM patients the Danish Myeloma Registry representing entire population Denmark from 2005–2013. Two-thousand two hundred and fifty three (90%) presented with reduction below lower normal levels of at least one uninvolved immunoglobulin. Using multivariable Cox...
Abstract Purpose: This multicenter, first-in-human study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of BI-505, a human anti-ICAM-1 monoclonal antibody, in advanced relapsed/refractory multiple myeloma patients. Experimental Design: BI-505 was given intravenously, every 2 weeks, at escalating doses from 0.0004 to 20 mg/kg, with extension therapy until disease progression for responding or stable patients receiving 0.09 mg/kg higher doses. Results: A total 35 were...
Matching adjusted indirect comparisons (MAICs) were performed to compare the efficacy of cilta-cel versus elotuzumab + pomalidomide dexamethasone (EloPd), isatuximab carfilzomib (IsaKd), (IsaPd), and selinexor bortezomib (SVd) in patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy are lenalidomide-refractory. Unanchored MAICs using individual patient-level data (IPD) for all apheresed randomized arm CARTITUDE-4 (n = 208) published...
Abstract Objectives Multiple myeloma ( MM ) patients are at high risk of developing infections. The factors for blood stream infections BSI in are, however, less described. aim this study was to analyze the epidemiology and an unselected population. Methods Nationwide Danish data 1154 diagnosed from 2010 2013 were linked with nationwide on cultures BC s; 2016) assess peak period having a taken positive pathogenic microorganisms. Results highest number day −30 +180 date diagnosis. Risk...
Abstract Objectives Infections pose the greatest risk of early death in patients with Multiple Myeloma. However, few studies have analyzed factors for infections Myeloma patients. The aim this study was to analyze within a population‐based MM cohort. Methods Using Danish registries (from 2005 2013), we all ICD‐10 codes first 6 months diagnosis 2557 Results Pneumonia and sepsis represented 46% infections. Multivariable regression analysis showed that pneumonia were male gender (HR 1.4; P =...
ABSTRACT Aims/Background Recent agents have profoundly reshaped the multiple myeloma (MM) landscape. Their real‐world impacts need to be assessed over long term. Methods EMMY is a non‐interventional, prospective dynamic cohort, conducted in France, since 2017, with 900 patients enrolled each year. Newly diagnosed MM (NDMM) who initiated treatment from 2017 2020 are here described. Results A total of 1036 non‐transplant eligible (NTE) (median age: 74.9 years) and 561 received autologous stem...
7513 Background: LINVO, a T-cell redirecting BCMA×CD3 bispecific antibody, has demonstrated high efficacy and generally manageable safety in triple-class exposed (TCE: anti-CD38 Ab + immunomodulatory drug [IMiD] proteasome inhibitor [PI]) pts with RRMM. Combination treatment (tx) CFZ, potent second-generation PI, may enhance clinical activity via rapid cytoreduction complementary immunostimulatory mechanisms like immunogenic cell death antigen spreading. We report preliminary from dose...
Data on the impact of long term treatment with immunomodulatory drugs (IMiD) health-related quality life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 in newly diagnosed transplant ineligible patients multiple myeloma, comparing melphalan-prednisolone combination thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T MPR-R). EORTC QLQ-C30 and MY20 questionnaires were completed at baseline, after three nine induction cycles six 12...
Abstract Objective: Multiple myeloma (MM) accounts for approximately 15% of hematological cancers. Although still incurable, the prognosis MM has much improved within past two decades due to use high-dose chemotherapy (HDT) supported by autologous stem-cell transplantation (ASCT) eligible patients and a variety novel agents. How sequence these new potent treatments is growing challenge. While focus on efficiency tolerability, ultimate goal reestablishment preservation patients’...
Summary In 2019 the UK Myeloma Research Alliance introduced Risk Profile (MRP) for prediction of outcome in patients with newly diagnosed multiple myeloma (MM), ineligible autologous stem cell transplantation. To validate MRP a population‐based setting we performed study entire cohort transplant MM above 65 years Danish National Registry. Our data confirmed value MRP. 1,377 patients, score separated into three distinct risk‐groups an observed hazard ratio 2.91 early death high‐risk versus...
Although amino-bisphosphonates (N-BPs) induce apoptosis of myeloma cells in vitro, most in-vivo studies fail to demonstrate a corresponding antitumour effect. This discrepancy might reflect the development resistance effects N-BP when they are exposed for prolonged time. To test this hypothesis, two N-BP-sensitive human cell lines were continuously increasing concentrations alendronate 6 weeks. During treatment period, 10 out sublines developed reduced apoptotic and antiproliferative...
We evaluated the efficacy and safety of pomalidomide, bortezomib, dexamethasone (PVd) vs bortezomib (Vd) by age, renal function, high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse.OPTIMISMM was a phase 3, multicenter, open-label, randomized study (NCT01734928; N = 559). The primary endpoint progression-free survival (PFS).Overall, 226 had received one prior line therapy. PVd significantly prolonged PFS Vd aged ≤65 years (median,...
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Ophthalmology HomeNew OnlineCurrent IssueFor Authors Podcast Publications Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Oncology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy...
Quantification of free monoclonal light chains in urine [Bence Jones proteins (BJPs)] is used to diagnose multiple myeloma and evaluate response treatment. We have developed evaluated an optimized approach for quantification BJPs.High-resolution gel electrophoresis unconcentrated albumin calibrators was carried out on Sebia's Hydrasys instrument with Hydragel HR agarose gels. After staining acid violet, the gels were scanned densitometrically. The intensities BJP bands relative solutions...